文献速递神经头颈MR

免疫治疗对皮肤鳞癌神经周围播散的影像学反应

Response of Perineurial Tumor Spread from Cutaneous Squamous Cell Carcinoma Treated with Immunotherapy.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-09-14

这项回顾性研究纳入9例接受抗PD-1免疫治疗的皮肤鳞状细胞癌神经周围播散(PNS)患者,评估其影像学反应,并结合101例文献综述。结果显示最佳影像学反应为完全缓解3例、部分缓解5例、稳定1例,无进展病例,中位随访37个月;1例出现假性进展。提示抗PD-1治疗可实现持久的影像学控制,早期MRI恶化需谨慎解读为假性进展。

要点

  • 抗PD-1治疗皮肤鳞癌PNS可获得高客观影像缓解率,随访中无进展病例。
  • 治疗后早期MRI恶化可能为假性进展,不应贸然判定疾病进展。
  • 颅神经强化和增大的变化可作为整体治疗反应的替代标志物。

核心结论

  • 抗PD-1免疫治疗可能对皮肤鳞癌相关神经周围播散提供持久的影像学控制,客观缓解在MRI上可见。

研究设计与样本

  • 回顾性研究纳入9例接受抗PD-1治疗的皮肤鳞癌PNS患者,均有影像学监测,并进行叙述性文献综述。
  • 文献综述纳入101例接受免疫治疗的皮肤鳞癌相关PNS患者。

关键影像表现/征象

  • 基线PNS分区:1区(颅外)2例,2区(颅底/神经孔)0例,3区(颅内)7例。
  • 最佳影像学反应:完全缓解3例,部分缓解5例,稳定疾病1例,无进展病例,中位随访37个月。
  • 1例出现假性进展,表现为早期MRI恶化随后改善。
  • 颅神经强化和增大的变化可作为整体治疗反应的替代标志物。

诊断标准与关键数值

  • 文献综述中免疫治疗反应:完全缓解35%,部分缓解43%,稳定9%,进展10%,临床缓解1%,未知2%,假性进展1%。

临床应用与阅片要点

  • 阅片时需注意治疗后早期MRI恶化可能为假性进展,避免误判为疾病进展。
  • 关注颅神经强化和增大的变化,可作为评估整体治疗反应的影像学替代指标。

局限性

  • 回顾性研究,样本量小(9例),单中心,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Anti-programmed-death-1 receptor immune check point inhibitor (anti PD-1 ICI) therapy has shown benefit in advanced cSCC, however imaging response of PNS to immunotherapy remain incompletely characterized. This retrospective study included 9 patients with imaging surveillance of cSCC PNS treated with anti-PD-1 therapy, and narrative literature review of cSCC-associated PNS treated with immunotherapy. Baseline and follow-up imaging were evaluated for PNS zone, cranial nerve involvement, and treatment response. Zone 1 (extracranial) involvement was present in 2 patients, Zone 2 (skull base/foraminal) in 0 patients, and Zone 3 (intracranial) in 7 patients. Best imaging outcome was complete response (CR) = 3 patients, partial response (PR) = 5 patients, and stable disease (SD) = 1 patient. No patients had PNS progressive disease (PD) on surveillance imaging; median follow-up was 37 months. One patient had pseudoprogression (PsP), with early MRI worsening and subsequent improvement. Narrative literature review identified 101 patients, with CR = 35%, PR = 43%, SD = 9%, PD = 10%, clinical response in 1%, unknown 2%, and PsP = 1%. Anti-PD-1 immunotherapy may provide durable imaging control of cSCC-associated PNTS, with objective response visible on MRI. Early post-treatment MRI worsening should be interpreted cautiously as pseudoprogression and imaging response lag may occur. Changes in cranial nerve enhancement and enlargement can serve as a surrogate marker for overall response, which could broaden inclusion of PNS as a measure for clinical trials.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Gichamo F, Chang J, Park SJ, et al. Response of Perineurial Tumor Spread from Cutaneous Squamous Cell Carcinoma Treated with Immunotherapy. AJNR Am J Neuroradiol. 2026. PMID: 42735925. doi:10.3174/ajnr.A9637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。